Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis

BACKGROUND: Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs...

Description complète

Détails bibliographiques
Auteurs principaux: Akter, Ripa, Maksymowych, Walter P., Martin, M. Liam, Hogan, David B.
Format: Online Article Texte
Langue:English
Publié: Canadian Geriatrics Society 2020
Sujets:
Original Research
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Documents similaires